Pharma BD Deal Intelligence
Crucell halted shipments of Quinvaxem from its Shingal Korea facility due to microbiological contamination and took a €23M impairment charge during the J&J…
J&J's recommended public offer of €24.75 per share moves the company decisively into vaccines, building on the September 2009 18% strategic stake.
J&J reached 98.89% ownership at the end of the subsequent offering period, clearing the path for delisting and full integration into Janssen Pharmaceuticals.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J reached agreement on October 6, 2010 to acquire remaining ~82% of Crucell for €24.75/share, valuing Crucell at ~€1.75B (~$2.4B). J&J had bought 18% in 2009. Crucell became Janssen Vaccines.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Crucell N.V. (this deal) | 2010 | $2.4B | 47 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2010 deals · Johnson & Johnson deals · Vaccines deals